Trusted Press Release Distribution   Plans | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Precision Business Insights
www.precisionbusinessinsights.com
Rajesh k
sales@precisionbusinessinsights.com

Bookmark and Share
Bacteriophage Therapy Market | Size ,Share , Forecast 2019-2025
Bacteriophages (or “phages”) are viruses that can be found inside plants and animals and in soil, rivers, oceans and even sewers. Phages invade bacterial cells and inject their DNA into the bacterial target.

BriefingWire.com, 6/13/2019 - Bacteriophages (or “phages”) are viruses that can be found inside plants and animals and in soil, rivers, oceans and even sewers. Phages invade bacterial cells and inject their DNA into the bacterial target. Some phages can disrupt bacterial metabolism and cause the bacterium to disintegrate. The intentional application of phages to destroy bacteria is known as bacteriophage therapy.

Bacteriophage therapy or phage therapy is used to treat the pathogenic bacterial infections with viruses. These are more specific than bacteria and do not cause any harm to host organism as well as beneficial bacteria such as gut flora. Bacteriophages are most abundant in biosphere and isolated, concentrated, and applied in specific area to eradicate the bacteria. They cause the bacterium to lyse by disrupting the bacterial metabolism.

For request sample: ://precisionbusinessinsights.com/request-sample/?product_id=23847

The strengthening factor in the Bacteriophage therapy Increase in the incidence of antibiotic resistant bacteria. FDA approval for bacteriophage therapies, stringent regulations for the use of antibiotics, promising pipeline drugs under various stages of clinical trials, rise in funding from the public and private sector for bacteriophage therapy research, and wide range of applications with bacteriophage therapeutics are propel the bacteriophage therapy market over the forecast years.

Moreover, most of the bacteriophage therapy market players and research institutes are focused on the R&D activities to develop newer bacteriophage therapies to treat the chronic infections. For instance,

Precision Business Insights (PBI) in its report titled “Bacteriophage Therapy Market”: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 20XX-20XX and Forecast 20XX-20XX” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast.

• AmpliPHI Bioscieces Corporation developing the bacteriophage therapeutics AB-SA01 and AB-PA01. AB-SA01 is developed for the treatment of multi drug resistant aureus infections and completed the two Phase 1 studies. AB-PA01 developed for the treatment of P. aeruginosa infections and completed the pre-clinical studies

• Technophage received FDA clearance for its Investigational New Drug (IND) application to initiate the human clinical trials for bacteriophage TP-102 used in the treatment of chronic ulcers such as diabetic foot disease

• In January 2018, Pherecydes Pharma raised US$ 10.3 Mn Series B funding led by GO CAPITAL, ACE Management, and Auriga Partners to enter the clinical trials novel bacteriophages PHOSA for the treatment of Staphylococcus aureus infection and PNEUMOPHAGE for the treatment of Pseudomonas aeruginosa respiratory tract infections.

• In March 2017, Intralytix, Inc. received GRAS recognition from FDA for ShigaShield, a non-chemical antimicrobial preparation to control waterborne/foodborne bacterial pathogen Shigella including three major disease-causing species S, sonnei, S. flexneri, and S. dysenteriae. Moreover, company collaborated with Ferring Pharmaceuticals in bacteriophage-based inflammatory bowel disease (IBD) drug development project

For more information: precisionbusinessinsights.com/market-reports/bacteriophage-therapy-market

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2019 Proserve Technology, Inc.